Health
Moderna melanoma vaccine cuts death risk in Phase 3 trial
An experimental mRNA skin cancer vaccine from Moderna and Merck cut the risk of death and melanoma returning by 49 percent in a Phase 3 trial.
Bringing you stories that vibe with your fashion